Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Herceptin, and Radiation for Pancreatic Cancer
NCT00005926Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by National Cancer Institute. Started Jun 2000; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00005926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005926.